Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05487391 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Oct 1, 2028 to Aug 31, 2027 · Study sites: 0 to 1 · Completion date: Oct 1, 2031 to May 22, 2029 · 2 morev2 Show 5 more changesShow less
    • Primary completion date: Oct 1, 2028 to Aug 31, 2027
    • Study sites: 0 to 1
    • Completion date: Oct 1, 2031 to May 22, 2029
    • Start date changed from estimate of Oct 1, 2022 to Dec 8, 2022
    • Eligibility criteria revised

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the efficacy and safety of QL1706 combined with platinum-based chemotherapy versus placebo combined with platinum-based chemotherapy in adjuvant treatment of stage II-IIIB NSCLC without EGFR-sensitizing mutations and ALK fusions after complete surgical resection.The subjects were randomly divided into two groups according to 1:1, with about 316 subjects in the experimental group and the control group.
Trial Details
NCT Number NCT05487391
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Carcinoma, Non-Small-Cell Lung
Enrollment 632 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov